Back to Search
Start Over
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
- Source :
-
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 May; Vol. 27 (18). - Publication Year :
- 2022
-
Abstract
- We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
Details
- Language :
- English
- ISSN :
- 1560-7917
- Volume :
- 27
- Issue :
- 18
- Database :
- MEDLINE
- Journal :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
- Publication Type :
- Academic Journal
- Accession number :
- 35514304
- Full Text :
- https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322